anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This Phase I study will be conducted as a randomized, placebo-controlled, double-blind, dose-escalation study in four groups of healthy adult male and female subjects who are BCG-vaccinated, HIV-negative, and have no evidence of tuberculosis infection. The study will be conducted at one or two sites located in South Africa.

Forty subjects will be sequentially enrolled into one of four study groups (i.e., Group 1, Group 2, Group 3, or Group 4) based on time of completion of screening, with 10 subjects enrolled into each group. Within each study group, subjects will be randomized to a treatment regimen of either AERAS-404 or placebo control administered by intramuscular injection on Study Day 0 and Study Day 56. All subjects will receive the same treatment on Study Day 0 as they receive on Study Day 56. The dose of antigen will increase between study groups. All subjects will be followed for safety and immunogenicity evaluations for 182 days. A total of eleven clinic visits are planned (excluding screening) for all subjects.
Thioredoxin, a small dithiol protein, is a specific reductant for major food proteins, allergenic proteins and particularly allergenic proteins present in widely used foods from animal and plant sources. All targeted proteins contain disulfide (S-S) bonds that are reduced to the sulfhydryl (SH) level by thioredoxin. The proteins are allergenically active and less digestible in the oxidized (S-S) state. When reduced (SH state), they lose their allergenicity and/or become more digestible. Thioredoxin achieved this reduction when activated (reduced) either by NADPH via NADP-thioredoxin reductase (physiological conditions) or by dithiothreitol, a chemical reductant. Skin tests and feeding experiments carried out with sensitized dogs showed that treatment of the food with reduced thioredoxin prior to ingestion eliminated or decreased the allergenicity of the food. Studies showed increased digestion of food and food proteins by pepsin and trypsin following reduction by thioredoxin.
Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans every 24 weeks from baseline to Week 96 (5 scans), and monitoring of renal function at 4 and 12 weeks after baseline and every 12 weeks thereafter. With the exception of an enhanced monitoring protocol for bone and renal outcomes, participants will be managed according to local standards of care.
Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication and will be set on active mode for this group. The MM will display messages of encouragement to participants and education on the importance of taking their warfarin medication. The Med-eMonitor also features an alarm that will sound to remind participants to take their medication as scheduled. Participants in this group will also be entered into a daily lottery. On any given study day, participants have a 1 in 10 chance of winning $10 and 1 in 100 chance of winning $100 when taking their warfarin medication as prescribed. Participants must take their dose correctly in order to be eligible for the daily lottery.
The present invention relates to a composition for preventing, ameliorating or treating an inflammatory disease, which comprises beta-1, 3-glucan and a peptide consisting of the amino acid sequence of SEQ ID NO. 4, and also relates to an anti-inflammatory composition. The present invention also relates to an antimicrobial composition against a sepsis-causing bacterium, which contains β -1,3-glucan (β -1,3-glucan), a peptide consisting of the amino acid sequence of seq id No. 4, and an antibiotic. The present invention also relates to a method for preventing or treating inflammatory diseases, which comprises the step of administering beta-1, 3-glucan (beta-1, 3-glucan) and a peptide consisting of the amino acid sequence of sequence No. 4 to a patient. Therefore, when the β -1,3-glucan (β -1,3-glucan) of the present invention and the peptide consisting of the amino acid sequence of sequence No. 4 are included, the level of active oxygen, sepsis-causing bacteria or inflammatory cytokines can be reduced and the survival rate of septic mice can be significantly improved, and thus it is effective for a composition for preventing, ameliorating or treating inflammatory diseases such as sepsis or a method for preventing or treating the same. In particular, active oxygen caused by phagocytes can be significantly reduced, and when used in combination with antibiotics, the expression level or survival rate of active oxygen, sepsis-causing bacteria or inflammatory cytokines can be significantly improved, thus being more effective.
The hepatitis B elimination is a goal proposed by the WHO to be achieved by 2030 through the adoption of synergistic measures for the prevention and chronic HBV infection treatment. Complete cure is characterized by the HBV elimination from the body and is the goal of the chronic hepatitis B treatment, which once achieved, will enable the hepatitis B elimination. This, today, has been a scientific challenge. The difficulty in achieving a complete cure is due to the indefinite maintenance of a covalently closed episomal circular DNA (cccDNA) reservoir and the maintenance and persistence of an insufficient and dysfunctional immune response in chronically infected patients. Among the measures adopted to eliminate hepatitis B, two have the potential to directly interfere with the virus cycle, but with limited effect on HBV control. These are conventional vaccines-blocking transmission and antiviral therapy-inhibiting replication. Vaccines, despite their effectiveness in protecting against horizontal transmission and preventing mother-to-child vertical transmission, have no effect on chronic infection or potential to eliminate the virus. Treatment with antivirals suppresses viral replication, but has no curative effect, as it has no action against cccDNA. Therapeutic vaccines comprise an additional approach in the chronic infection treatment, however, they have only a modest effect on the immune system, enhancing it temporarily. This manuscript aims to address (1) the cccDNA persistence in the hepatocyte nucleus and the immune response dysfunction in chronically infected individuals as two primary factors that have hampered the treatment and HBV elimination from the human body; (2) the limitations of antiviral therapy and therapeutic vaccines, as strategies to control hepatitis B; and (3) the possibly promising therapeutic approaches for the complete cure and elimination of hepatitis B.
PURPOSE: Use of mesh is essential in hernia repair. A common complication after hernia repair is surgical site infection (SSI), which poses a risk in spreading to the mesh, possibly causing mesh infection. Topical antimicrobial pretreatment of mesh may potentially reduce SSI risk in hernia repair and has shown promising results in in vitro and in vivo studies. Clinical evidence, however, is more important. This systematic review aims to provide an overview of available clinical evidence for antimicrobial pretreated mesh in hernia repair surgery to reduce SSI.
METHODS: We report in accordance with PRISMA guidelines. CENTRAL, EMBASE, CINAHL and PubMed were searched up to October 2023 for studies that investigated the use of antimicrobial pretreated mesh on SSI incidence in adults undergoing hernia repair. The primary outcome was SSI incidence. We also collected data on pathogen involvement, hernia recurrence, and mesh infection. A meta-analysis on SSI risk and GRADE-assessment was performed of eligible studies.
RESULTS: We identified 11 eligible studies (n = 2660 patients); 5 randomized trials and 6 cohort studies. Investigated interventions included pre-coated mesh, antibiotic carriers, mesh soaked or irrigated with antibiotic or antiseptic solution. Meta-analysis showed no significant reduction in SSI for antibiotic pretreated polypropylene mesh (RR 0.76 [95% CI 0.27; 2.09]; I2 50%).
CONCLUSION: Data on topical mesh pretreatment to reduce SSI risk after hernia repair is limited. Very low certainty evidence from randomized trials in hernia repair surgery shows no significant benefit for antibiotic mesh pretreatment for SSI reduction, but data are imprecise due to optimal information size not being met.
The invention discloses solid composition with valsartan and a preparation method of the solid composition with the valsartan. The solid composition with the valsartan comprises a compound preparation of the valsartan or a unilateral preparation of the valsartan. Quality content of ethyl acetate in valsartan atmospheric pressure ionization (API) residual solvent of the solid composition is smaller than 0.30%, and preferably, is smaller than 0.15%. Due to the fact that control of midbodies, such as particles, mixed powder, in the preparation process of the solid composition is adopted, final quality content of moisture of the solid composition is guaranteed to be smaller than 3.5%. Quality content of valsartan ethyl ester of the solid composition is less than 0.2% under the condition of quickened stability for 6 months. The solid composition with the valsartan and the preparation method of the solid composition with the valsartan have the advantages that due to the fact that the content of the ethyl acetate in valsartan API residual solvent is controlled, the solid composition with the valsartan with high quality is produced.
Motor vehicle crashes are the major cause of death and disability among adolescents from 16 through 20 years of age. While adolescents between the ages of 16 and 19 years constitute only 5% of all licensed drivers, they are involved in 15% of the crashes in which they or other occupants are killed. In fact, 16-year-old drivers are more than 20 times as likely to have a crash as the general population of drivers and 17-year-olds are more than 6 times as likely. In addition, for each adolescent motor vehicle fatality, approximately 100 nonfatal injuries occur, making crashes the leading cause of disability due to head and spinal cord injuries in adolescents.

Parents can have a huge impact on adolescent behavior. However, the impact of parenting practices on adolescent driving behavior has not yet been examined. This study aims to determine the efficacy of an intervention designed to increase parents' involvement in, and parental restrictions on, their teens' early driving experiences in order to reduce the number of tickets and crashes among teen drivers. The intervention provides educational materials to parents and adolescents from the time the adolescent gets a learner's permit through the first 6 months of licensure. These persuasive communications are tailored to adolescents' level of driving experience. The intervention materials make explicit the increased risk associated with adolescent driving and methods for reducing risk through increased parental involvement in and restriction of driving.

Participants were recruited in the Connecticut Department of Motor Vehicle offices as adolescents applied for their learner's permits. Participants were randomized to either the intervention group or the control group. The control group received standard information about driving not related to the specific teen risks focused on in the intervention group materials. All participants completed interviews at study entry, licensure, 3 months after licensure, 6 months after licensure, and 12 months after licensure. Parents were asked about their expectations and parenting practices regarding their adolescents' driving behaviors. Adolescents were asked about their driving practices and their parents' rules and restrictions regarding driving. The driving records for each adolescent were obtained from the state motor vehicle administration and examined 18 months after licensure.
Children and adolescent participants with anxiety disorder receive cognitive behavioral therapy (CBT) for a 12-week period. In the final eight weeks of the trial, the subjects complete the control intervention before a CBT session: Part 1. dot-probe task, where a target is equally randomly presented at the previous location of the neutral or the simultaneously presented threatening stimulus. Part 2. visual search, where the targets are equally randomly presented distal of neutral and threatening distractors.
Mutations in GATA2, a critical hematopoietic transcription factor, underlie a complex congenital disorder characterized by immunodeficiency, bone marrow failure, and lymphatic/vascular dysfunction. Patients with GATA2 deficiency may suffer from a striking variety of diseases including severe and recurrent infections, myelodysplasia/leukemia, pulmonary alveolar proteinosis, lymphedema, sensorineural hearing loss, and possibly susceptibility to other malignancies, autoimmune disorders, thrombotic events, and miscarriage. Mutations in GATA2 appear to be fully penetrant, but expressivity is remarkably variable, even among related individuals. Disease may also manifest at nearly any age ranging from early childhood to late adulthood, the reasons for which remain poorly understood.

While considerable progress has been made towards better understanding this complex congenital disorder, many important questions remain unanswered: What is the full spectrum of clinical disease and the associated pathophysiology? What accounts for the remarkable variability in age of onset and clinical phenotype? What are the optimal strategies for disease diagnosis and management? This natural history protocol is designed to further characterize the clinical phenotype of GATA2 deficiency, better understand the reasons for phenotypic variability, better understand disease progression over time, standardize the diagnostic evaluation, and facilitate the screening of at risk relatives. Up to 300 males and females greater than or equal to 2 years old with proven mutations in GATA2 or clinical and laboratory characteristics strongly consistent with GATA2 deficiency will initially undergo a series of baseline laboratory tests and diagnostic procedures at the NIH. Follow-up laboratory testing will be conducted at yearly visits for up to 15 years; additional follow-up diagnostic procedures will be conducted based on clinical need.
A method of recording a state of an apheresis machine or a dialysis machine having a disposable component disposed thereon. The disposable component has tubing and a blood component bag. The disposable component is configured to be installed on the apheresis device or dialysis machine by a human operator. The method includes acquiring with a camera an image of a forward-facing external surface portion of the apheresis machine or dialysis machine and the tubing and the blood component bag of the disposable component. The image is acquired automatically without requiring user input. The method includes recording medical device information for the apheresis machine or dialysis machine comprising the image. The method includes generating a message comprising the image and transmitting the message comprising the image to a remote computer.
An active dry preparation of papaine or similar vegetable protease is obtained by mixing it with a mixture of dry yeast containing emulsin, and seed containing amygdalin or with seed containing both amygdalin and emulsin.  Liberation of hydrogen cyanide and subsequent activation occur only when the preparation is moistened.  The seed is de-husked, de-oiled, and pulverized before admixture.  Suitable seeds are plum, apricot, peach, almond, cherry, apple, quince, red currant, poppy, lucerne, lentil, lupin, ricinus, cocoa, soya, olive, pumpkin, oat, barley, and germinant corn.  In an example, 50 parts by weight papaine, 30 parts yeast, and 20 parts cocoa seed are admixed.ALSO:An active dry preparation of papain or similar vegetable protease is obtained by mixing it with a mixture of dry yeast containing emulsin, and seed containing amygdalin or with seed containing both amygdalin and emulsin.  Liberation of hydrogen cyanide and subsequent activation occur only when the preparation is moistened.  The seed is de-husked, de-oiled, and pulverized before admixture.  Suitable seeds are plum, apricot, peach, almond, cherry, apple, quince, red currant, poppy, lucerne, lentil, lupin, ricinus, cocoa, soya, olive, pumpkin, oat, barley, and germinant corn.  In an example, 50 parts by weight papain, 30 parts yeast, and 20 parts cocoa seed are admixed.
PURPOSE:To provide a composite transfusion containing a reducing sugar, physiological amino acid and electrolyte at specific balanced ratio, excellent from nutritional viewpoint, and capable of suppressing the browning phenomenon. CONSTITUTION:The objective composite transfusion essentially resistant to discoloration can be prepared by using a reducing sugar (e.g. glucose, maltose, etc.), physiological amino acids, and electrolytes of the table I at ratios and amounts shown in the table. The concentration product of the reducing sugar and amino acid is preferably 7-25, especially 12-24 to improve the stability of the transfusion. The pH of the transfusion is preferably 4.0-6.0. It can be prepared according to the method used in the preparation of transfusion or injections, and may be sterilized by heating. Since the transfusion can be used as it is without combining with other agent, various problems caused by the combined use, e.g. variation of pH, contamination with microorganisms and foreign materials, etc., can be avoided.
Adverse reactions have occurred with corticosteroid/anti-infective combination drugs which can be attributed to the corticosteroid component, the anti-infective component, or the combination. Exact incidence figures are not available since no denominator of treated patients is available.

Reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitizations. The reactions due to the corticosteroid component are: elevation of intraocular pressure (IOP) with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing.

Corticosteroid-containing preparations have also been reported to cause perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, and conjunctival hyperemia have occasionally been reported following use of steroids.
The invention relates to a method for producing a subunit vaccine against canine parvovirus (CPV) and other related viruses (FPLV and MEV). The method is comprised of a first step to obtain a recombinant protein VP2 of CPV using the replication of a recombinant baculovirus, wherein the gene corresponding to the VP2 had been previously introduced in cells of a permissive host. The protein VP2 obtained in this invention has the capacity of forming empty chimeric capsides with high immunogenicity so that they can be formulated into vaccines for protecting animals against infection caused by CPV, FPLV and MEV. Additionnaly they may be chemically or genetically engineered in order to incorporate epitopes corresponding to other viral proteins and they may be used in the formulation of polyvalent vaccines. The recombinant baculovirus AcMNPV.pCPVEx17 expresses the protein VP2 of the virus CPV in conditions which enable it to form pseudo-viral capsides and has been deposited at the ECACC. Said vaccine finds application in the veterinary field.
The present invention relates to a bioenvironment-sensitive nanoparticle comprising a polymer with a complementary charge. The present invention further relates to a production method thereof and a pharmaceutical use thereof. According to the present invention, the nanoparticle stays in a stable state in an environment outside a cell. Thus, efficient and stable delivery of a target molecule such as a drug is possible even with a small quantity. Furthermore, the nanoparticle of the present invention tends to be specific in the cancer cell environment. Thus, the cancer cell-specific diagnosis or treatment is possible as well.
BACKGROUND: Acute decompensated heart failure (ADHF) is a leading cause of cardiovascular disease hospitalisations associated with significant morbidity and mortality. In hospitals, HF patients are typically managed by cardiology or physician teams, with differences in patient demographics and clinical outcomes. This study utilises contemporary HF registry data to compare patient characteristics and outcomes in those with ADHF admitted into General Medicine and Cardiology units.
METHODS: The Victorian Cardiac Outcomes Registry was utilised to identify patients hospitalised with ADHF 30-day period in each of four consecutive years. We compared patient characteristics, pharmacological management and outpatient follow-up of patients admitted to General Medicine and Cardiology units. Primary outcome measures included in-hospital mortality, 30-day readmission, and 30-day mortality.
RESULTS: Between 2014 and 2017, a total of 1,253 patients with ADHF admissions were registered, with 53% admitted in General Medicine units and 47% in Cardiology units. General Medicine patients were more likely to be older (82 vs 71 years; p<0.001), female (51% vs 34%; p<0.001), and have higher prevalence of comorbidities and preserved left ventricular function (p<0.001). There were no differences in primary outcome measures between General Medicine and Cardiology in terms of: in-hospital mortality (5.0% vs 3.9%; p=0.35), 30-day readmission (23.4% vs 23.6%; p=0.93), and 30-day mortality (10.0% vs 8.0%; p=0.21).
CONCLUSIONS: Hospitalised patients with HF continue to have high mortality and rehospitalisation rates. The choice of treatment by General Medicine or Cardiology units, based on the particular medical profile and individual needs of the patients, provides equivalent outcomes.
This study was planned to enrol 24 pregnant women with 34+0-38+6 GW preterm labour with confirmed gestational diabetes mellitus (GDM) or diabetes mellitus in combination with pregnancy in a dose exploratory study in this population. A total of 12 subjects were enrolled in the full-dose group to receive 5 mg dexamethasone (intramuscular injection, q12h, 4 doses) and 12 subjects were enrolled in the half-dose group to receive 2.5 mg dexamethasone (intramuscular injection, q12h, 4 doses).
Two-weeks screening period and a 4-weeks open-label intralesional treatment period with L19IL2/L19TNF. Pembrolizumab will be administered by i.v. infusion on the first day of intralesional treatment with L19IL2/L19TNF, and will continue every 3 weeks for approximately 2 years, 35 cycles, 2 year cap or until disease progression or unacceptable toxicity, whichever comes first.